1 Full-length article

- 2 Title page
- 3

4 Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome:
5 results from a single Italian Centre study on tocilizumab versus standard of
6 care.

7

8 Authors: Luca Quartuccio1, prof, MD, PhD, Arianna Sonaglia1, MD, Dennis McGonagle2, prof, MD, PhD, Martina Fabris3, MD, Maddalena Peghin4, MD, Davide Pecori4, MD, Amato De 9 Monte5, MD, Tiziana Bove5,6, prof, MD, Francesco Curcio2, prof, MD, PhD, Flavio Bassi5, MD, 10 Salvatore De Vita1*, prof, MD, Carlo Tascini4*, MD 11 12 *equally collaborated to this work. 13 14 Affiliations: 1Clinic of Rheumatology, Department of Medicine (DAME), ASUFC, University of 15 Udine, Udine, Italy; 2National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), Leeds Teaching Hospitals, Leeds, UK; 3Institute of Clinical Pathology, ASUFC, 16 Udine, Italy; 4Infectious Diseases Unit, ASUFC, Udine, Italy; 5Department of Anesthesia and 17 18 Intensive Care, ASUFC, Udine, Italy; 6Department of Medicine, Anesthesia and Intensive Care Clinic, University of Udine, Udine, Italy. 19 **Correspondence to:** 20 Luca Quartuccio, MD, PhD; ORCID iD: 0000-0002-0134-6439. 21 22 Clinic of Rheumatology, ASUFC 23 Department of Medicine (DAME), University of Udine, Udine, Italy 24 Email to: luca.quartuccio@asufc.sanita.fvg.it 25 Phone: +39 0432559808

- 26 Fax to: + 39 0432559472
- 27
- 28 Keywords: coronavirus, COVID-19, tocilizumab, cytokine, intensive care
- 29 Manuscript word count: 2500
- 30 **Tables: 4**
- 31 **Figures: 1**
- 32 Supplemental file: 1
- 33

34 Highlights

- There is an urgent need for markers of prognosis in COVID-19.
- Higher inflammatory markers best select tocilizumab treatment.
- The ward based tocilizumab group showed better responses and less infections than ICU
- 38 tocilizumab group.
- The former group may be the best for evaluating the impact of anti-cytokine therapy in COVID-
- 40 19.
- The known poor risk factors for COVID-19 infection were present in the TOCI treated rather
- 42 than in the good prognosis standard of care group.

44 Abstract [250 words]

45 **Objective**

Approximately 5% of patients with coronavirus disease 2019 (COVID-19) develop a lifethreatening pneumonia that often occurs in the setting of increased inflammation or "cytokine storm". Anti-cytokine treatments are being evaluated but optimal patient selection remains unclear, and the aim of our study is to address this point.

50 Methods

51 Between February 29 to April 6, 2020, 111 consecutive hospitalized patients with COVID-19 52 pneumonia were evaluated in a single centre retrospective study. Patients were divided in two 53 groups: 42 severe cases (TOCI) with adverse prognostic features including raised CRP and IL-6 54 levels, who underwent anti-cytokine treatments, mostly tocilizumab, and 69 standard of care 55 patients (SOC).

56 **Results**

57 In the TOCI group, all received anti-viral therapy and 40% also received glucocorticoids. In TOCI, 62% of cases were ventilated and there were 3 deaths (17.8 ± 10.6 days, mean follow up) with 7/26 58 59 cases remaining on ventilators, without improvement, and 17/26 developed bacterial superinfection. One fatality occurred in the 15 TOCI cases treated on noninvasive ventilation and 1 serious 60 61 bacterial superinfection. Of the 69 cases in SOC, there was no fatalities and no bacterial complications. The TOCI group had higher baseline CRP and IL-6 elevations (p<0.0001 for both) 62 63 and higher neutrophils and lower lymphocyte levels (p=0.04 and p=0.001, respectively) with the TOCI ventilated patients having higher markers than non-ventilated TOCI patients. 64

65 **Conclusion**

Higher inflammatory markers, more infections and worse outcomes characterized ventilated TOCI
cases compared to ward based TOCI. Despite the confounding factors, this suggests that therapy
time in anti-cytokine randomized trials will be key.

70 Funding

- 71 This research received no external funding.
- 72 **Conflicts of Interest:** "The authors declare no conflict of interest."

74 Introduction

75 The outbreak of novel coronavirus 2019 (COVID-19) caused by severe acute respiratory syndrome 76 coronavirus 2 (SARS-CoV-2) is a global pandemic [1]. About twenty-five percent of patients have 77 a seriously ill disease. A fraction of them may develop a very severe pneumonia which may 78 progress to acute respiratory distress syndrome (ARDS) or end-organ failure that may be associated 79 with a cytokine storm syndrome [2]. Laboratory features associated with ARDS or death included 80 neutrophilia, coagulation dysfunction [e.g., higher lactate dehydrogenase (LDH) and D-dimer] [3]. 81 Markedly high levels of interleukin (IL)-2R, IL-6, IL-10, and TNF- α and the absolute numbers of 82 CD4+ and CD8+ T lymphocytes being markedly low seem to characterize the most severe cases 83 [4]. Starting from the first preliminary experience on the apparent efficacy of tocilizumab in 84 COVID-19 pneumonia [5], many multicenter trials are ongoing to test anti-cytokine treatments in 85 critically ill patients.

86

87 Nevertheless, robust data to predict the outcome of COVID-19 pneumonia after the hospital 88 admission are still lacking [6], though they are urgently needed in order to facilitate the assessment 89 of anti-cytokine treatment efficacy in worse prognosis patient groups and not milder disease. The 90 aim of this retrospective study was to evaluate baseline laboratory and immunological features in 91 patients hospitalized for COVID-19 pneumonia and to explore such parameters in relationship to 92 standard of care (SOC group) therapy versus anti-cytokine therapy, mainly tocilizumab, (TOCI 93 group) that was mostly used either in ventilated patients in the ICU or non-invasively ventilated 94 patients, mostly in the ward setting. Our single centre experience and approach showed that the 95 milder hospitalized SOC group faired well as did cases with cytokine storm treated with 96 tocilizumab outside of the ICU setting without ventilator support. Severe complications including 97 bacterial infections complicated tocilizumab in the ICU setting but not ward-based tocilizumab 98 therapy. Therefore, randomized trials should target non-ICU patients to prevent cytokine storm 99 evolution.

100

101 Methods

This study was undertaken to identify laboratory features for more serious COVID-19 disease (i.e., to determine which cases that might theoretically benefit from anti-cytokine drugs). In this monocentric retrospective case-control study, the clinical and immunological characteristics of 111 consecutive patients with COVID-19 were analyzed. Patients were admitted to our hospital from February 29 to April 6, 2020. All but 6 patients presented to our hospital with 6 cases transferred from three other hospitals (all of whom eventually received tocilizumab).

108

Oral or written consent was obtained from patients. The study was conducted in accordance with
the ethical principles of the Helsinki Declaration and ethical approval was given by local Ethics
Committee (CEUR-2020-Os-102).

112

113 Besides clinical evaluation, the level of CRP and IL-6, when available, guided the decision towards 114 anti-cytokine treatments. Clinical decisions for the treatment of all these patients were taken usually 115 within the first week after the admission, and during this time, the laboratory tests were repeated. 116 Demographic, clinical and laboratory characteristics, treatments and outcome data were collected. 117 Identification of cases of COVID-19 virus was based on the detection of unique sequences of virus RNA by nucleic acid amplification tests (NAAT) such as RT-PCR with confirmation by nucleic 118 119 acid sequencing. The following genes were investigated: E gene for screening and then RdRp and N 120 genes of SARS-CoV-2 for confirmation [7].

121

Some laboratory data analysed at the admission are reported in table 1, including flow cytometry
analysis with antibodies for the following subpopulations: CD19+ B cells, CD3+CD4+ T cells,
CD3+CD8+ T cells, CD56+ NK cells, platelet count (cell/microL) and serum IL-6 (pg/ml),

125 measured by CE_IVD electrochemiluminescence immunoassay (Elecsys IL6, Cobas, physiological

126 range < 7pg/ml) with results being available within 48 hours.

127

128 Variables were reported as mean and standard deviation or median and interquartile range (IQR), as 129 appropriate, or frequency rates and percentages if categorical; consequently, comparisons between 130 TOCI and SOC groups were made by parametric tests (t-test for two independent samples) or no 131 parametric tests (Mann-Whitney test) for continuous variables. Proportions were compared by χ^2 132 test, or Fisher exact test. Bivariate correlation was made by two tailed Pearson or Spearman tests. All statistical analyses were performed using SPSS version 15.0 software (SPSS Inc). For 133 134 unadjusted comparisons, a 2-sided α of less than .05 was considered statistically significant. No 135 corrections were made for multiple comparisons due to the explorative nature of the study.

136

When the laboratory parameters were available, the patients were classified into two groups: the first group comprised 42 cases who developed a serious COVID-19 disease that were deemed suitable for tocilizumab 8 mg/kg intravenously as a single infusion. In TOCI failures, two patients were then treated with anakinra 200 mg/day subcutaneously for three consecutive days. A second group of 69 cases who received supportive therapy [standard of care group (SOC)] comprised those initially admitted to the hospital for COVID-19, and who were treated with SOC based on clinical and laboratory features (Table 1).

144

145 **Results**

146 **Patients' characteristics and outcome**

Table 1 reports the main demographic and clinical features of the two groups. Patients were predominantly male (77/111, 69.4%) with a mean age of 58.5 ± 13.6 years. Patients in TOCI were slightly older than SOC (p=0.02) (table 1). Globally, at the hospital admission, resting oxygen saturation equal or below 93% was available for 45 patients (40.5%).

151

Antiviral treatments were employed in 100% of TOCI group and 80% of SOC group (Table 1).
Notably, nearly 40% of TOCI group received glucocorticoids but none of the SOC group did (Table
1). There was no difference between groups regarding the time of reaching a negative swab test
(supplemental file).

156

Among TOCI group, 18 (43%) patients were originally referred to the Infectious Disease Unit with 3 being subsequently transferred to ICU before tocilizumab administration (Figure 1) with 24/42 patients (57%) ICU transfers within 24 hours of hospital admission. The majority of patients received tocilizumab in the ICU (27/42, 64.3%) with the remaining 15 cases receiving TOCI on the ward. Tocilizumab was administered after a mean time of 8.4 ± 3.7 days from disease onset as addon treatment. Of the 27 patients that were transferred to ICU, 26 (96.3%) were intubated with subsequent tracheostomies in 8 (7.2%), while only one was on noninvasive ventilation.

164

There were no fatalities in the SOC group (Figure 1). Overall, at April 18, 2020, 4/42 TOCI patients had died (9.5%). Of the TOCI ventilated patients 15/26 (57.7%) had a good outcome. When combined with fatality rate, 11/26 (42.3%) patients in the TOCI ventilated group can be deemed as non-responders. By contrast, 15/16 (93.7%) TOCI non-ventilated patients can be deemed as responders with a single fatality (Figure 1). Importantly, at the hospital admission, TOCI patients who required invasive ventilation showed higher levels of inflammation markers, higher LDH and lower lymphocyte count than non-ventilated TOCI patients (Table 2).

Eighteen out 111 patients (16.2%) experienced bacterial superinfection that were almost exclusively in the TOCI group (Figure 1). Three out of four deaths and 17/18 bacterial complications occurred in ICU (all 3 deaths as well as all the bacterial complications occurred in patients on ventilators or in the non-ventilated TOCI group (Figure 1).

While all the patients in the SOC group recovered, in the TOCI group, 9/42 (21.4%) patients completely recovered, and 21/42 (50%) patients showed a clear and rapid improvement after tocilizumab. A rapid improvement on anakinra after tocilizumab occurred in one case. In the 21 recovered TOCI treated group complicating infections arose in 11 (52.4%). In the remaining 12 non-responder patients, four of them died, including one treated with anakinra after tocilizumab failure, and almost all showed co-morbidities including hypertension, obesity, ischemic heart disease or diabetes, or experienced superinfections, which substantially complicated the course.

184

185 Retrospective laboratory marker comparison between treatment groups

At hospital admission, TOCI group showed a significantly higher level of systemic inflammation as resulted by the significant difference of CRP levels [mg/L, median (IQR)] [79.05 (47.8-186.22) vs 24.1 (7.3-72.6) p<0.0001)], and IL-6 levels [pg/mL, median (IQR)] [63.5 (37.25-135.5) vs 18.5 (10.25-33), p<0.0001]. Also, some other laboratory features mirrored a higher level of systemic disease and organ damage in TOCI group, such as LDH [IU/L, median (IQR)] [625 (482-829) vs 442 (375-577), p=0.001] and CK [IU/L, median (IQR)] [134 (84.5-365.5) vs 93 (57-146), p=0.007].

192

The TOCI group showed a significantly higher neutrophil count (cells/microL) [4565 (3062.5-6190) vs 3670 (2285-4905), p=0.04], lower lymphocyte count [cell/microL, median (IQR)] [685 (545-1022.5) vs 940 (760-1195), p=0.001], CD4+ T cell [244.5 (158.75-406.25) vs 370 (269.5-497), p=0.02], CD8+ T cell subpopulation [77 (48-195.75) vs 180 (111-366), p=0.004]. Also, neutrophil to lymphocyte ratio (NLR) was significantly higher in TOCI group than in SOC group [5.6 (3.5-11.8) vs 3.6 (2.2-5.4), p=0.001]. The TOCI group also showed basal higher levels of LDH (p=0.001) and CK (p=0.007), possibly indicating cardiac injury that is a known bad prognostic sign.

Table 3A reports the correlations between CRP levels and the levels of the other biomarkers in the whole population (TOCI+SOC) and in the whole population after excluding those patients with the

203	worst clinical presentation at the admission (N=24). A moderate to high correlation (>0.5) was
204	found between CRP and the following variables: D-dimer, LDH, neutrophil count and NLR (table

205 2).

By excluding those patients admitted to the ICU within 24 hours (i.e., the most serious) (table 3B),

207 CRP and IL-6 remained statistically significant as discriminant variables between the two groups

208 (Table 3). Yet, correlations between CRP and IL-6, total white blood cell count, neutrophil count,

209 NLR, LDH were still significant (table 3B).

Furthermore, the same analysis in the whole cohort by splitting the two group (N=42 for TOCI and

211 N=69 for SOC), showed that baseline CRP value correlated with IL-6, D-dimer, LDH, WBC,

neutrophil count and NLR only in the SOC group, while in the TOCI group, baseline CRP

correlated only with LDH, WBC, neutrophil and NLR (data not shown).

214

215 Discussion

216

217 Our retrospective study was designed to evaluate which baseline standardized laboratory features in 218 hospitalized COVID-19 pneumonia may facilitate optimal employment of experimental anti-219 cytokine therapy [8, 9]. Some case reports and one case series on the treatment with tocilizumab 220 have been reported in the literature, suggesting some benefits in seriously ill patients [10-16]. More 221 clearly, our data suggested that tocilizumab treatment in patients with cytokine storm features may 222 be more effective outside of the ICU setting in non-ventilated patients. However, there were 223 differences in the degree of inflammation between non-ventilated and ventilated patients treated 224 with tocilizumab, so it cannot be inferred that use of tocilizumab prior to ICU admission is superior, 225 given the generally milder inflammation in the former group. Also, serious superimposed bacterial 226 infections were largely confined to the ICU. More worryingly, half the ICU ventilated patients 227 treated with TOCI remain ventilated or have died with only half of this group showing meaningful 228 clinical improvement so far.

229

Our findings confirmed that the milder patient group receiving standard of care therapy without the utilization of tocilizumab all made full recoveries. Our findings do point towards trials focused on the earlier use of such therapeutic strategies. Notably, our SOC and TOCI groups were different in terms of co-treatments, which could have affected the overall outcome, and all of the TOCI cases also received antiviral therapy. These findings are preliminary and the results of ongoing randomized controlled trials will definitely clarify anti-cytokine use.

236

237 In our study, neutrophilia, lymphopenia, in particular low CD8+ T cell count rather than CD4+ T 238 cell, higher CRP, higher LDH and higher CK showed the highest significance to distinguish the two 239 patient groups at initial hospital admission. Also, serum IL-6 was significantly higher in the TOCI 240 group, thus reflecting the very high inflammatory state of those patients at baseline. Very recently, 241 IL-6 serum levels were also closely correlated with viral load in critically ill patients and it is 242 important to point out that all our patients belonging to TOCI group received anti-viral agents [17]. 243 Notably, baseline CRP and IL-6 continued to distinguish the two groups (TOCI versus SOC) even 244 after excluding the most seriously ill patients from analyses. Thus, these biomarkers could useful 245 for decision making. Notably, a higher NLR, as well as a higher monocyte to lymphocyte ratio, 246 have been associated with mortality and imaging progression in hospitalized patients for COVID-19 [18-20]. It is well known that NLR is a biomarker for poor outcome even in various cancers [21]. 247

248

Lymphocyte biology probably plays a great role in the pathogenesis of COVID-19 disease [4, 22-250 25].

Since CD4+ T cells and CD8+ T cells are a crucial arm against infections [26], our findings also indicated that the lymphopenia in the TOCI group may be relevant for secondary infections. Given that, treatment with tocilizumab might favor the persistence of the virus and iatrogenic infections.

Anakinra might be safer and more flexible than repeating tocilizumab infusion in seriously ill patients.

256

257 A role for anticoagulation is increasingly recognized in severe COVID-19 [27, 28]. In our study, a 258 significant correlation between CRP and D-dimer, as well as with LDH and neutrophil count (and 259 NLR) was shown. Very recent data showed that low molecular weight heparin or unfractionated 260 heparin at prophylactic doses are associated with a reduced short-term mortality in more severe 261 COVID-19 patients [28], and most of our patients, particularly, in ICU, were administered heparin 262 which may have impacted on the overall outcome. Moreover, inflammatory diseases carry a higher 263 risk of thrombosis, as seen in chronic autoimmune diseases [29]. It remains to be seen whether the 264 possible efficacy of anti-cytokine therapy may be even to mitigate against immunothrombosis. 265 Increased levels of LDH and CK may also reflect the level of the organ damage in a systemic 266 disease, as occurs in the macrophage activation syndrome [30], where a hypercoagulable state often 267 complicates the course, and it may be the case for COVID-19. Thus, it is not surprisingly that LDH 268 has been already noticed as biomarker of severity as long as neutrophils, in COVID-19 [3, 31].

269

270 This study has several limitations. It is a retrospective study, with some missing data due to the 271 emergency context in which it has been realized. No conclusions on the efficacy and safety of 272 treatment approach employed can be provided. Six patients were transferred from other hospitals so 273 original baseline values from the first admission were unavailable. About 50% of the TOCI group 274 were admitted to the ICU within 24 hours from admission, thus they already presented a more 275 serious disease at the time of admission. The follow-up was limited from our hospital admission to 276 discharge. Finally, measurement of viral load was not available. Nevertheless, the cohort is 277 monocentric and it showed similar characteristics to those reported by Wang et al. [2], thus 278 supporting the results, though preliminary.

280 To conclude, our study showed that TOCI treated patients COVID-19 pneumonia were at the 281 highest risk of cytokine storm [32]. Tocilizumab use prior to ventilation in ICU may be optimal since 50% of such cases died, remain ventilated and show serious superinfection. Whether the use 282 283 of tocilizumab prior to ventilation will be vindicated in randomized trials is of major interest. Our 284 findings also showed that cases receiving tocilizumab on ventilation generally had higher levels of 285 inflammation than non-ventilated TOCI treated subjects, possibly suggesting that the latter group 286 has an intrinsically milder disease with a better prognosis. Timing of anti-cytokine therapy is a key 287 issue.

288

289 **Contributions**

LQ designed data collection tools, monitored data collection for the whole study, wrote the statistical analysis plan, cleaned and analysed the data, drafted and revised the paper. He is guarantor. AS collected the data, analysed the data, and revised the paper. FC, MF, TB, ADM, FB, MP, DP collected the data, analysed the data, and revised the paper. SDV, DM analysed the data, drafted and revised the paper. CT designed data collection tools, analysed the data, revised the paper.

296

297 Acknowledgements

298 We thank the following colleagues for their valued contribution to this work: Ginevra De Marchi,

299 MD, Miriam Isola, prof, BS, Sara Zandonella, MD, Ivan Giovannini, MD, Elena Treppo, MD,

300 Donatella Colatutto, MD, Marco Binutti, MD, Giulia Del Frate, MD, Roberto Agarinis, MD,

301 Valeria Manfrè, MD, Daniela Cesselli, prof, MD, Roberta Giacomello, BS, Federica D'Aurizio,

302 MD, Michele Zuliani, MD, Corrado Marescalco, MD.

303

304 Funding info

305 This research received no external funding.

307 Ethical approval information

308	The study was conducted in accordance with the ethical principles of the Helsinki Declaration.
309	Patients' consents for using data for research purpose were obtained at the time of hospital
310	admission.
311	Ethical approval for the present retrospective observational study was given by "Comitato Etico
312	Unico Regionale (CEUR)", with the following registration number: CEUR-2020-Os-102.
313	Patients treated with tocilizumab were then enrolled into the observational part of the TOCIVID-19
314	Italian study (EudraCT: 2020-001110-38), a single arm, open-label trial on the efficacy and safety
315	of tocilizumab in COVID-19 pneumonia.
316	
317	Data sharing statement
318	The data that support the findings of this study are available on request from the corresponding
319	author, [LQ].
320	
321	References
322	1. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel
323	coronavirus in Wuhan, China. Lancet 2020; 395: 497-506.
324	2. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019
325	Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Feb 7. doi:
326	10.1001/jama.2020.1585.
327	3. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress
328	Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan,
329	China. JAMA Intern Med. 2020 Mar 13. doi: 10.1001/jamainternmed.2020.0994.
330	4. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate
331	coronavirus disease 2019. J Clin Invest. 2020 Apr 13. pii: 137244. doi: 10.1172/JCI137244.

- 5. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single
 center experience. *J Med Virol.* 2020 Apr 6. doi: 10.1002/jmv.25801.
- 6. Wynants L, Van Calster B, Bonten MMJ, et al. Prediction models for diagnosis and
 prognosis of covid-19 infection: systematic review and critical appraisal. *BMJ*. 2020 Apr
 7;369:m1328. doi: 10.1136/bmj.m1328.
- 337 7. Udugama B, Kadhiresan P, Kozlowski HN, et al. Diagnosing COVID-19: The Disease and
- Tools for Detection ACS Nano. 2020 Mar 30: acsnano.0c02624. Published online 2020 Mar 30. doi: 10.1021/acsnano.0c02624.
- 8. Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of 340 341 people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical 342 immunologists from China. Clin Immunol. 2020 25;214:108393. Mar doi: 343 10.1016/j.clim.2020.108393
- McGonagle D, Sharif K, O'Regan A, Bridgewood C. The Role of Cytokines including
 Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like
 Disease. *Autoimmun Rev.* 2020 Apr 3:102537. doi: 10.1016/j.autrev.2020.102537
- 347 10. Xu XL, Han MF, Li TT, et al. Effective treatment of severe COVID-19 patients with
 348 tocilizumab. *ChinaXiv*. 2020;202003(00026):V1.
- 11. Michot JM, Albiges L, Chaput N, et al. Tocilizumab, an anti-IL6 receptor antibody, to
 treat Covid-19-related respiratory failure: a case report. *Ann Oncol.* 2020 Apr 2. pii: S09237534(20)36387-0. doi: 10.1016/j.annonc.2020.03.300.
- 12. De Luna G, Habibi A, Deux JF, et al. Rapid and Severe Covid-19 Pneumonia with Severe
- Acute Chest Syndrome in a Sickle Cell Patient Successfully Treated with Tocilizumab. *Am J Hematol.* 2020 Apr 13. doi: 10.1002/ajh.25833.
- 13. Cellina M, Orsi M, Bombaci F, Sala M, Marino P, Oliva G. Favorable changes of CT
 findings in a patient with COVID-19 pneumonia after treatment with tocilizumab. *Diagn Interv Imaging*. 2020 Mar 31. pii: S2211-5684(20)30087-5. doi: 10.1016/j.diii.2020.03.010.

- 14. Di Giambenedetto S, Ciccullo A, Borghetti A, et al.; GEMELLI AGAINST COVID-19
- 359 group (Members are listed in the Acknowledgments section). Off-label Use of Tocilizumab
- in Patients with SARS-CoV-2 Infection. *J Med Virol.* **2020** Apr 16. doi: 10.1002/jmv.25897.
- 361 15. Fu B, Xu X, Wei H. Why tocilizumab could be an effective treatment for severe COVID-
- 362 19? J Transl Med. 2020 ;18(1):164. doi: 10.1186/s12967-020-02339-3.1
- 16. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single
 center experience. *J Med Virol.* 2020 Apr 6. doi: 10.1002/jmv.25801.
- 17. Chen X, Zhao B, Qu Y, et al. Detectable serum SARS-CoV-2viral load (RNAemia) is
 closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-
- 367 19 patients. *Clin Infect Dis.* 2020 Apr 17;ciaa449. doi: 10.1093/cid/ciaa449.
- 18. Liu Y, Du X, Chen J, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for
 mortality in hospitalized patients with COVID-19. *Clin Infect Dis.* 2020 Mar 12. pii:
 ciaa248. doi: 10.1093/cid/ciaa248.
- 371 19. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19
 372 in Wuhan, China. *J Infect.* 2020 Apr 10. pii: S0163-4453(20)30208-5. doi:
 373 10.1016/j.jinf.2020.04.002.
- 20. Yang Z, Shi J, He Z, et al. Predictors for imaging progression on chest CT from coronavirus
 disease 2019 (COVID-19) patients. *Aging (Albany NY)*. 2020 Apr 10; 12. doi:
 10.18632/aging.102999.
- 21. Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte
 ratio in solid tumors: a systematic review and meta-analysis. *J Natl Cancer Inst.* 2014;106
 (6):dju124. doi: 10.1093/inci/dju124.
- 22. Ji D, Zhang D , Xu J, et al. Prediction for Progression Risk in Patients with COVID-19
 Pneumonia: the CALL Score. *Clin Infect Dis.* 2020 Apr 9. pii: ciaa414. doi:
 10.1093/cid/ciaa414.

- 23. Yang X, Yu Y, Xu J, et al. Clinical Course and Outcomes of Critically Ill Patients With
- SARS-CoV-2 Pneumonia in Wuhan, China: A Single-Centered, Retrospective,
 Observational Study. *Lancet Respir Med.* 2020 Feb 24. pii: S2213-2600(20)30079-5. doi:
- 386 10.1016/S2213-2600(20)30079-5.
- 24. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in
 China. *N Engl J Med.* 2020 Feb 28. doi: 10.1056/NEJMoa2002032.
- 25. Xiong Y, Liu Y, Cao L, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid
 and peripheral blood mononuclear cells in COVID-19 patients. *Emerg Microbes Infect.*2020; 9: 761-770. doi: 10.1080/22221751.2020.1747363.
- 26. Zhao J, Zhao J, Mangalam AK, et al. Airway Memory CD4(+) T Cells Mediate Protective
 Immunity against Emerging Respiratory Coronaviruses. *Immunity*. 2016; 44: 1379-91. doi:
 10.1016/j.immuni.2016.05.006.
- 27. Ciceri F, Beretta L, Scandroglio AM, et al. Microvascular COVID-19 lung vessels
 obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory
 distress syndrome working hypothesis. *Crit Care Resusc.* 2020 Apr 15.
- 28. Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased
 mortality in severe coronavirus disease 2019 patients with coagulopathy. *J Thromb Haemost*2020; doi: 10.1111/jth.14817.
- 29. Quartuccio L. Risk of thrombosis in Sjögren syndrome: the open question of endothelial
 function immune-mediated dysregulation. *J Rheumatol.* 2017; 44: 1106-8. doi:
 10.3899/jrheum.170462.
- 30. Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19
 inpatients in Wuhan. *J Allergy Clin Immunol.* 2020 Apr 12. pii: S0091-6749(20)30495-4.
 doi: 10.1016/j.jaci.2020.04.006.
- 407 31. Henderson LA, Canna SW, Schulert GS, et al. On the alert for cytokine storm:
 408 Immunopathology in COVID-19. *Arthritis Rheumatol.* 2020 Apr 15. doi: 10.1002/art.41285.

- 409 32. Quartuccio L, Semerano L, Benucci M, Boissier MC, De Vita S. Urgent avenues in the
- 410 treatment of COVID-19: targeting downstream inflammation to prevent catastrophic
- 411 syndrome. *Joint Bone Spine* **2020**; 87: 191-3.

Table 1. Main comparisons between treatment groups at day 0 (hospital admission).

	TOCI (N=42)	Number of available observations, N (%)	SOC (N=69)	Number of available observations, N (%)	P value
Age, mean±SD	62·4±11·8	42 (100)	56·2±14·2	69 (100)	0.02
Gender, male (%)	33 (78.6)	42 (100)	44 (63.8)	69 (100)	0.1
Days from onset to admission, median (IQR)	6 (3·25-7)	42 (100)	7 (3-9.5)	69 (100)	0.18
Hypertension (%)	20 (47.6)	42 (100)	21 (30.4)	69 (100)	0.11
Charlson's index ≥ 2 (%)	5 (11.9)	42 (100)	12 (17.4)	69 (100)	0.44
Antivirals* (%)	42 (100)	42 (100)	54 (78.3)	69 (100)	0.003
Antimalarials** (%)	39 (92.9)	42 (100)	53 (76.8)	69 (100)	0.05
Glucocorticoids*** (%)	16 (38.1)	42 (100)	0	69 (100)	<0.0001
Antibiotics# (%)	12 (28.6)	42 (100)	9 (23.1)	69 (100)	0.07
LMWH (%)	31 (73.8)	42 (100)	15 (21.7)	69 (100)	<0.0001
WBC count (cells/microL), median (IQR)	,	39 (92.9)	5230 (3705- 6305)	69 (100)	0.14
Neutrophil count (cells/microL), median (IQR)		34 (80.2)	3670 (2285- 4905)	69 (100)	0.04
Lymphocytes (cells/microL), median (IQR)	685 (545-	34 (80·2)	940 (760- 1195)	69 (100)	0.001
Neutrophil/lymphocyte ratio, median (IQR)	5.6 (3.5-11.8)	34 (80.2)	3.7 (2.2-5.4)	69 (100)	0.001
CD4+ T cells (cells/microL), median (IQR)		24 (57.1)	370 (269·5- 497)	25 (36·2)	0.02
CD8+ T cells (cells/microL), median (IQR)		24 (57.1)	180 (111- 366)	25 (36·2)	0.004
CD19+ B cells (cells/microL), median (IQR)	,	17 (40.5)	112·5 (83- 174·5)	24 (34.8)	0.12
CD56+ NK cells (cells/microL), median (IQR)		17 (40.5)	150 (131- 237)	23 (33·3)	0.16
Platelet count (cells/microL), median (IQR)		39 (92.8)	166000 (136000- 216500)	69 (100)	0.24
CRP (mg/L), median (IQR)	,	40 (95.2)	,	69 (100)	<0.0001
D-dimer (ng/ml), median (IQR)	835 (602- 1163)	14 (33·3)	660 (270·5- 846·5)	25 (36·2)	0.1
LDH (IU/L), median (IQR)	625 (482- 829)	35 (83.3)	442 (375- 577)	67 (97.1)	0.001
CK (IU/L), median (IQR)	134 (84·5- 365·5)	29 (69.0)	93 (57-146)	65 (94.2)	0.007
IL-6 (pg/ml), median (IQR)	63·5 (37·2- 135.5)	34 (80.9)	18·5 (10·25- 33)	56 (81.1)	<0.0001

414 Legend: SD, standard deviation; WBC, white blood cells; CRP, C-reactive protein; LDH, lactate

- 415 dehydrogenase; CK, creatine kinase; LMWH, low molecular weight heparin; BIOLOGIC, anti-
- 416 cytokine treatment group; SOC standard of care group.
- *Lopinavir/Ritonavir (L/R) in 56 patients (all as first-line antiviral treatment); Darunavir/Cobicistat
- 418 (D/C) in 57 patients (as first-line antiviral treatment in 40, as second-line in 17); Remdesivir in 3
- 419 patients, all as second- or third-line treatment. Seventeen patients switched from L/R to D/C due to
- 420 side effects.
- 421 **Hydroxychloroquine in 87 patients; chloroquine in 5 patients.

***Glucocorticoids were always administered intravenously at the dose of 1 mg/kg of
methylprednisolone in the first two days, then steroids were tapered and finally suspended in 7
days.

425 #as prophylactic treatment, before tocilizumab therapy.

427

	5 1		
	TOCI on NIV/O2 (N=16)	TOCI on ventilators (N=26)	P value
CRP, mg/L	59.3 (21.6-112.7)	114.6 (5.25-210)	0.04
IL-6, pg/ml	58 (28.45-78.5)	78.8 (46-161)	0.06
WBC, cell/microL	4425 (3210-6115)	6180 (5230-8130)	0.009
Neutrophil, cell/microL	3130 (2310-4885)	7235 (5430-9072)	0.01
Lymphocyte, cell/microL	1020 (635-1165)	650 (445-775)	0.01
NLR	3.5 (2.5-5.1)	8.2 (4.7-15.7)	0.001
LDH, IU/L	494 (246.5-599)	744 (580.75-1057)	0.001
CK, IU/L	101 (78-179)	197 (104.5-382.75)	0.13
(IQR).	d cell count; NLR, neutrophi		

428 **Table 2**. Laboratory marker comparison between the two Tocilizumab treated subgroups.

Variable	Spearman's rho correlation coefficient	P value	Number of observations, N (%)		
IL-6	0.46	<0.0001	90 (81.1)		
D-dimer	0.63	<0.0001	39 (35.1)		
LDH	0.62	<0.0001	102 (91.9)		
СК	0.23	0.03	94 (84.7)		
Total WBC count	0.49	<0.0001	108 (97.3)		
Neutrophil count	0.60	<0.0001	103 (92.8)		
Lymphocyte count	-0.26	0.002	103 (92.8)		
NLR	0.57	<0.0001	103 (92.8)		

Table 3A. Bivariate correlations between CRP levels and other biomarkers.

Legend: IL, interleukin; LDH, lactate dehydrogenase; CK, creatine kinase; WBC, white blood cell

count; NLR, neutrophil to lymphocyte ratio.

Table 3B. Bivariate correlations between CRP levels and other biomarkers by excluding those

patients transferred to ICU within 24 hours from the admission (N=24).


Variable	Spearman's rho correlation coefficient	P value	Number of observations, N (%)
IL-6	0.42	0.0002	71 (63.4)
D-dimer	0.62	0.0002	31 (27.9)
LDH	0.48	<0.0001	82 (73.9)
СК	0.12	0.29	78 (70.3)
Total WBC count	0.43	<0.0001	87 (78.4)
Neutrophil count	0.50	<0.0001	83 (74.8)
Lymphocyte count	-0.1	0.38	83 (74.8)
NLR	0.44	<0.0001	83 (74.8)

Legend: IL, interleukin; LDH, lactate dehydrogenase; CK, creatine kinase; WBC, white, blood cell


count; NLR, neutrophil to lymphocyte ratio.

466 Legend to the figure

467	Figure	1.	The	chart	illustrates	the	outcomes	of	the	two	treatment	groups.
-----	--------	----	-----	-------	-------------	-----	----------	----	-----	-----	-----------	---------



- 469 Legend: TOCI, anti-cytokine group; SOF, standard of care group; MOF, multi-organ failure; ICU,
- 470 intensive care unit; NIV, noninvasive ventilation; PE, pulmonary embolism.



group
SOC
+ 0-censored
+ 1-censored

Group	Total N. pts	N. Events	Time, days [median, IQR]
SOC	61	59	19 [15-26]
тосі	40	34	22 [11-33]
Overall	101	93	21 [14-27]